Stockreport

Viridian Therapeutics shares fall over 30% after trial data disappoints [Yahoo! Finance]

Viridian Therapeutics, Inc.  (VRDN) 
PDF Shares of Viridian Therapeutics (NASDAQ:VRDN) fell more than 30% Monday morning following the release of topline results from the company's REVEAL-1 trial in active thy [Read more]